graphic version rss
innovate, educate, improve lives
Home | Calendar | About Us | Our Offices |
Search: [Go]
Lawn & Garden
Family & Home
Money & Business
Food & Health
Environment &
Natural Resources
Kids & Teens

 more...>Intellectual Property>Success and Statistics>


TransGenRx, a biopharmaceutical manufacturing company, has developed technology that significantly reduces the cost of producing protein-based drugs by using a high-expressing avian cell line combined with their patented vector system. Patented and patent pending processes allow TGRx to develop custom proteins to meet a wide range of specifications. Dr. Richard Cooper, a professor in the AgCenter Department of Veterinary Science, serves as the company's Executive Vice President of Research and Development. Since its inception, the company has won an STTR phase II award and has won contracts with drug manufacturers for its proteins and hormones.

June 6, 2003
LSU AgCenter Announces Biotechnology Breakthrough

August 2005
TGRx Wins 2005 ‘Quality Award’ from U.S. Army 

October 28, 2009
TransGenRx gets $30 million contract with Argentinean company

February 9, 2012
TransGenRx signs agreement with Novocyt

To find more information about TransGenRx, visit:
Last Updated: 10/24/2012 12:27:52 PM

Have a question or comment about the information on this page?
Click here to contact us.